PMID- 27759482
OWN - NLM
STAT- MEDLINE
DCOM- 20171024
LR  - 20181202
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 28
IP  - 4
DP  - 2017 Jun
TI  - Dermatologic uses of omalizumabtitle.
PG  - 332-337
LID - 10.1080/09546634.2016.1249819 [doi]
AB  - PURPOSE: Omalizumab is a recombinant humanized monoclonal antibody that inhibits 
      the binding of immunoglobulin E (IgE) to the high-affinity IgE receptor (FceRI) 
      on the surface of mast cells and basophils. Omalizumab has been approved for use 
      in asthma, and new reports show promise in a variety of dermatologic diseases. 
      Herein, we review the literature on omalizumab in dermatology and discuss the 
      safety, efficacy and mechanisms of action for this emerging therapy. MATERIALS 
      AND METHODS: PubMED, MEDLINE and Embase databases were searched for the period 1 
      January 1990 to 1 September 2016. Articles sourced were graded according to the 
      Oxford Center for Evidence-Based Medicine Levels of Evidence Grades of 
      Recommendation criteria. RESULTS: A total of 99 articles met our inclusion 
      criteria. They included reports on the use of omalizumab in chronic spontaneous 
      urticaria, atopic dermatitis, mastocytosis, hyper-IgE syndrome, bullous 
      pemphigoid, Netherton syndrome, urticarial vasculitis, Churg-Strauss syndrome and 
      toxic epidermal necrolysis. CONCLUSIONS: Omalizumab is effective in a variety of 
      recalcitrant immune-mediated and autoimmune skin disorders. It is a safe and 
      effective treatment for use in chronic idiopathic urticaria (Grade of 
      recommendation: A). Randomized clinical trials with long-term follow-ups are 
      warranted to firmly establish the role of omalizumab in the treatment of 
      dermatologic disease.
FAU - Chia, Justin C
AU  - Chia JC
AD  - a Division of Dermatology, Department of Medicine , University of Calgary , 
      Calgary , Alberta , Canada.
FAU - Mydlarski, P Regine
AU  - Mydlarski PR
AD  - a Division of Dermatology, Department of Medicine , University of Calgary , 
      Calgary , Alberta , Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161107
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Allergic Agents/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal/adverse effects/therapeutic use
MH  - Autoimmune Diseases/drug therapy/immunology
MH  - Chronic Disease
MH  - Dermatitis, Atopic/drug therapy/immunology
MH  - Guidelines as Topic
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Omalizumab/adverse effects/immunology/*therapeutic use
MH  - Pemphigoid, Bullous/drug therapy/immunology
MH  - Skin Diseases/*drug therapy/immunology
MH  - Urticaria/drug therapy/immunology
OTO - NOTNLM
OT  - Omazliumab
OT  - bullous pemphigoid
OT  - eczema
OT  - urticaria
EDAT- 2016/10/21 06:00
MHDA- 2017/10/25 06:00
CRDT- 2016/11/08 06:00
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
PHST- 2016/11/08 06:00 [entrez]
AID - 10.1080/09546634.2016.1249819 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2017 Jun;28(4):332-337. doi: 10.1080/09546634.2016.1249819. 
      Epub 2016 Nov 7.